World Pharma Today

  All4Labels Global Packaging Group , a global leader in digital and sustainable labeling solutions, has undertaken a significant expansion of its operations in South Africa. The Group has made strategic investments in infrastructure and technology to enhance its services in the region, marking a milestone in the company’s growth strategy. With the acquisition of a production  site in Durban  18 months ago, All4Labels expanded its market presence in South Africa. Since then, the Group has successfully integrated the facility into its global network, ensuring it aligns with the company’s high standards and operational policies. With this integration now being completed, the site will play a key role in advancing the company’s labeling services in the South African market. The South African region is strategically important for All4Labels as part of its broader growth objectives. The Group is committed to delivering outstanding value to its customers, currently served in th...

  Drug development is a long and complex process that starts with discovery and, if successful, ends with government approval for marketing. Each step in the drug development process, outlined below, has specific goals with the aim of down-selecting appropriate hits and candidates to an approved drug substance. Here, we discuss the relevant objectives and techniques used in each stage of antibody drug development. Discovery The discovery phase is broken down into early and late-stage discovery. The primary goal of the discovery stages is to remove any sequence with undesired performance considering both chemical instabilities and target binding. Discovery will start with a large panel of antibodies that may range from hundreds to thousands and be reduced to a pool in the tens. To reduce the panel, in silico screening is commonly used as a primary tool because sample availability is very scarce at this stage. In silico screening uses computer simulations or virtual screening tools t...

  [LEIDEN, NL] – Life Science Newswire – Synexa Life Sciences, a global provider of biomarker and bioanalytical solutions to the pharmaceutical, biotech, and CRO industries, has proudly achieved the My Green Lab Certification at the highest ‘Green’ level at its Cape Town, South Africa facility. Laboratories play a crucial role in advancing healthcare but are among the most resource-intensive environments in the life sciences industry. Synexa is committed to implementing and enhancing sustainability practices throughout the organisation, without any compromise on quality or scientific excellence. Achieving the My Green Lab Certification at the ‘Green’ level will enable Synexa to further support the increasing customer demand for ethical and environmentally conscious clinical studies. The certification process, which commenced in 2024, involved implementing numerous sustainability measures across various departments including lab operations, research practices, supply chain, procurem...

  CPHI & PMEC China (June 24-26 th ) returns to the Shanghai New International Expo Center amid a marked surge in international interest, with industry momentum rebounding following a string of positive developments in global trade and pharmaceutical investment. The 2025 edition is set to become the largest pharma event ever held in Asia, with more than 90,000 attendees and over 12,000 international executives expected. The recent trade tariff reprieve[1], alongside an improving global outlook for pharma – i.e. higher valuations and improved capital expenditure by biotech and big pharma – is transforming into greater international interest at CPHI & PMEC China. International executives will visit the event in record numbers as pharma companies look for new ingredient suppliers and equipment providers. Another key trend emerging is the increasing interest from global pharmaceutical companies in Chinese biotech assets – not only for access to the domestic market, but als...

  Syntegon delivers record results in 2024 New strategy fuels accelerated growth following CEO transition in late 2023 Order intake increased by 11% to 1.8 billion EUR and revenue grew by 7% to 6 billion EUR Strong EBITDA improvement by 15% to 222 million EUR and 14% EBITDA margin (up 100 bps) Focused cash flow generation program delivers strong improvement Strategic focus on turnkey solutions for the global Pharmaceutical and Biotech industries Accelerated growth and further results improvement targeted in 2025 Waiblingen, May 15, 2025 – The Syntegon Group, a leading strategic partner to the global pharmaceutical, biotech and food industries, reported record results for fiscal year 2024. Driven by its newly introduced corporate strategy focused on growth, operational excellence and long-term value creation, Syntegon achieved accelerated growth, strong profitability, and improved cash flow. Strategic initiatives launched in 2024 included targeted investments in portfolio expansion ...

  Based on available data from US FDA between Aug 2017 to Feb 2024, approximately 31% of injectable drug recalls were due to the presence of particulates contamination [1]. Even as improvement measures are being adopted by the pharmaceutical manufacturers to reduce the occurrence of particulate-related recalls, the issue of particulates in drugs continues to be an important topic that is scrutinized by US FDA. In December 2021, US FDA further introduced a draft guidance for industry ‘Inspection of Injectable Products for Visible Particulates’, which emphasizes the importance of using ‘a holistic, risk-based approach to visible particulate control that incorporates product development, manufacturing controls, visual inspection techniques, particulate identification, investigation, and corrective actions designed to assess, correct, and prevent the risk of visible particulate contamination’. Although the United States Pharmacopeial (USP) General Chapters, such as USP <787>, ...